The arena of dry eye disease (DED) has become its own area of expertise, requiring a thorough knowledge of the etiologic, diagnostic, and therapeutic options and approaches in order to achieve a pristine ocular surface.
Ocular allergy completes the triad that can affect the ocular surface. Patients may have perennial allergies caused by dust mites and/or animal dander or may have seasonal allergies caused by tree, grass, and/or ragweed pollens. All forms of allergy treatment (topical, intranasal, inhaled aerosols, and/or systemic) will typically cause dry eye and/or dry mouth as a side effect of treatment, complicating an already complex ocular surface. [HLA]-DR), tear osmolarity, tear film thickness of the lipid layer, nonspecific inflammatory markers of the tear film such as metalloproteinase-9 (MMP-9), immune blood titers, and meibomian gland dropout in the tarsus. Quantifying tear osmolarity (Tear Lab) is a reliable method to diagnose aqueous deficiency and monitor a patient's response to treatment in general. A tear osmolarity greater than 308 mOsm/l in either of the two eyes measured and/or a difference of greater than 8 mOsm/l between the two eyes is a hallmark of tear film instability. [11] [12] [13] No different from a diabetic measure of glycated hemoglobin (HbA 1C ) as a measure of blood sugar control, tear osmolarity is a good measure of dry eye severity and therapeutic response.
Research has even shown high osmolarity to be associated with an increase in MMP-9 and a loss of epithelial cell-cell junctions. 14 way due to its consistent moderate pressure between 0.8 g/mm² and 1.2 g/ mm². 22 Korb et al. showed a statistically significant correlation between the number of meibomian glands that will express liquid using the MGE device and the severity of symptom level patients had for their dry eye concerns by utilizing the SPEED questionnaire in this study.
22,23
The International Task Force (ITF) created consensus guidelines in terms of diagnostic signs and symptoms and treatment considerations. 
Therapeutic Options for Dry Eye
The ITF delineated treatment recommendations based the level of dry eye severity diagnosis. Topical cyclosporine 0.5 % (Restasis LipiFlow thermal pulsation (TearScience) as aided by the lipid layer LipiView analysis can be more definitive in the treatment of evaporative dry eye.
LipiFlow Thermal Pulsation System is truly an advanced treatment option for MGD/evaporative dry eye patients and can effectively and safely treat meibomian gland obstruction in both the upper and lower eyelids simultaneously as an in-office procedure, taking only 12 minutes per eye.
The LipiFlow system utilizes a sterile disposable eyepiece connected to a digital console used by the clinician to control the application of heat and pressure to the eyelids 33 (see Figure 1) . The lid warmer resembles a large oval scleral lens designed to rest on the bulbar conjunctiva and vaults the cornea. The concave side to the lid warmer comprises an insulating material that, in addition to the air gap created by the corneal vault, shields the cornea and ocular surface from direct exposure to the heat applied.
The convex side of the lens warmer contains an imbedded precision heater to regulate the temperature applied to the inner surface of the eyelids, LipiFlow treatment statistically increased mean meibomian gland secretion score from a mean of 6.3 at baseline to a mean of 16.7 at 4 weeks (see Figure   2 ). LipiFlow treatment significantly improved mean TBUT from a mean of 5.5
seconds at baseline to a mean of 7.4 seconds at 4 weeks (see Figure 3) .
Lastly, LipiFlow statistically decreased the frequency and severity of dry eye symptoms based on SPEED score questionnaire post treatment (see Figure 4 ). There was similar improvement in effectiveness trends observed after crossover from warm compress therapy to LipiFlow treatment as well.
In terms of safety, there were no unanticipated or serious device-related adverse events reported with LipiFlow. There was no ocular allergy flareups related to the treatment either as this was a localized heat therapy to the meibomian glands and not to the entire ocular surface. There was no difference in mean change in intraocular pressure (IOP) of logMAR best spectacle-corrected visual acuity (BSCVA) from baseline to after treatment in the LipiFlow versus control group. On a 0 to 10 comfort scale, mean (± standard deviation [SD]) patient discomfort score was 1.4±1.4 during LipiFlow and 0.2±0.6 immediately after treatment. In the study, as directed in the device labeling, two drops of topical anesthetic (e.g., proparacaine or tetracaine) were instilled prior to device insertion. This was to facilitate insertion by reducing the sensation on the eye (cornea/conjunctiva).
However, the discomfort during the LipiFlow procedure is primarily from the pressure application to the eyelid, and these topical anesthetic drops do very little to anesthetize the pressure feeling to the eyelid. In addition, the effects of these drops begin to wear off prior to completion of the 12-minute procedure. Based on a published study, the anesthesia from 1 drop of proparacaine lasts 10.7 minutes and 1 drop of tetracaine lasts 9.4 minutes. 35 Therefore, the anesthetic effects on the eye sensation are likely 
